Literature DB >> 31896443

Prevention and early treatment of driveline infections in ventricular assist device patients - The DESTINE staging proposal and the first standard of care protocol.

Alexander M Bernhardt1, Thomas Schlöglhofer2, Volker Lauenroth3, Florian Mueller4, Marcus Mueller5, Alexandra Schoede6, Christian Klopsch7.   

Abstract

Mechanical circulatory support (MCS) using left ventricular assist devices (LVAD) have considerably improved the quality of life and survival rate of patients with end-stage heart failure. Despite substantial technological progress, major challenges with regard to VAD-specific and VAD-related infections have hitherto hindered the broader application of this promising therapy approach. Driveline infections (DLI) range among the main adverse events experienced in LVAD patients. However, many centers still apply their own protocol for driveline exit site (DLES) care and an international standard on prevention, reduction and early treatment of DLI after the perioperative period has not yet been defined. In March 2019, VAD coordinators and cardiac surgeons from Germany and Austria met to develop a standard of care procedure (SOP) as well as a new staging approach with recommended actions for treatment of VAD carriers. In this Driveline Expert STagINg and carE (DESTINE) study group we developed a 10-step SOP for DLES care with emphasis on essentials such as clean and save preparation, sterile dressing change and secure driveline immobilization. An advanced wound staging approach was defined with recommended actions for prevention, early detection and stage-related management of DLI. Broad consensus was reached on the fact that an interdisciplinary approach both in DLES care and DLES healing disorder awareness is required to prolong infect-free survival times on MCS as well as to ensure high patient compliance and quality of life. In conclusion, a new detailed SOP for appropriate DLES care and an advanced wound staging approach for prevention and management of DLI were defined on an expert level applicable for VAD clinicians, practitioners and care givers in Central Europe.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  DESTINE; Driveline exit site; Driveline infections; Early detection; Left ventricular assist devices; Prevention; Staging

Year:  2019        PMID: 31896443     DOI: 10.1016/j.jcrc.2019.12.014

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  10 in total

1.  Association Between Care Fragmentation and Total Spending After Durable Left Ventricular Device Implant: A Mediation Analysis of Health Care-Associated Infections Within a National Medicare-Society of Thoracic Surgeons Intermacs Linked Dataset.

Authors:  K Dennie Kim; Russell J Funk; Hechuan Hou; Austin Airhart; Khalil Nassar; Francis D Pagani; Min Zhang; P Paul Chandanabhumma; Keith D Aaronson; Carol E Chenoweth; Ahmad Hider; Lourdes Cabrera; Donald S Likosky
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-09-06

Review 2.  Decreasing driveline infections in patients supported on ventricular assist devices: a care pathway approach.

Authors:  Julia Seretny; Tara Pidborochynski; Holger Buchholz; Darren H Freed; Roderick MacArthur; Nicole Dubyk; Laura Cunliffe; Osiris Zelaya; Jennifer Conway
Journal:  BMJ Open Qual       Date:  2022-05

3.  Driveline Infection in Left Ventricular Assist Device Patients: Effect of Standardized Protocols, Pathogen Type, and Treatment Strategy.

Authors:  Heidi S Lumish; Barbara Cagliostro; Lorenzo Braghieri; Bruno Bohn; Giulio M Mondellini; Karen Antler; Vivian Feldman; Audrey Kleet; Jennifer Murphy; Melie Tiburcio; Kathryn Fidlow; Douglas Jennings; Gabriel T Sayer; Koji Takeda; Yoshifumi Naka; Ryan T Demmer; Justin G Aaron; Nir Uriel; Paolo C Colombo; Melana Yuzefpolskaya
Journal:  ASAIO J       Date:  2022-03-01       Impact factor: 3.826

4.  Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection.

Authors:  Sebastian V Rojas; Simon Junghans; Henrik Fox; Kanstantsin Lazouski; Rene Schramm; Michiel Morshuis; Jan F Gummert; Justus Gross
Journal:  Antibiotics (Basel)       Date:  2022-04-29

Review 5.  Ventricular Assist Device-Specific Infections.

Authors:  Yue Qu; Anton Y Peleg; David McGiffin
Journal:  J Clin Med       Date:  2021-01-25       Impact factor: 4.241

6.  Driveline Features as Risk Factor for Infection in Left Ventricular Assist Devices: Meta-Analysis and Experimental Tests.

Authors:  Melanie Kranzl; Martin Stoiber; Anne-Kristin Schaefer; Julia Riebandt; Dominik Wiedemann; Christiane Marko; Günther Laufer; Daniel Zimpfer; Heinrich Schima; Thomas Schlöglhofer
Journal:  Front Cardiovasc Med       Date:  2021-12-16

7.  Left ventricular assist device driveline infections in three contemporary devices.

Authors:  Thomas Schlöglhofer; Peter Michalovics; Julia Riebandt; Philipp Angleitner; Martin Stoiber; Günther Laufer; Heinrich Schima; Dominik Wiedemann; Daniel Zimpfer; Francesco Moscato
Journal:  Artif Organs       Date:  2020-11-28       Impact factor: 3.094

8.  Prevalence and management of driveline infections in mechanical circulatory support - a single center analysis.

Authors:  Tomasz Dziodzio; Mariusz Kuśmierczyk; Andrzej Juraszek; Mikołaj Smólski; Piotr Kołsut; Jarosław Szymański; Paweł Litwiński; Krzysztof Kuśmierski; Joanna Zakrzewska-Koperska; Maciej Sterliński
Journal:  J Cardiothorac Surg       Date:  2021-08-03       Impact factor: 1.637

9.  Driveline exit-site care protocols in patients with left ventricular assist devices: a systematic review.

Authors:  Zeliha Ozdemir Koken; Yunus C Yalcin; Diana van Netten; Chantal C de Bakker; Maaike van der Graaf; Umit Kervan; Nelianne J Verkaik; Kadir Caliskan
Journal:  Eur J Cardiothorac Surg       Date:  2021-09-11       Impact factor: 4.191

Review 10.  Systems of conductive skin for power transfer in clinical applications.

Authors:  Andreas P Kourouklis; Julius Kaemmel; Xi Wu; Evgenij Potapov; Nikola Cesarovic; Aldo Ferrari; Christoph Starck; Volkmar Falk; Edoardo Mazza
Journal:  Eur Biophys J       Date:  2021-09-03       Impact factor: 1.733

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.